Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 9/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16616563 | 1.00 | RELA (0.51) | RELAABCG2CTSLCTSBABCB1 | |
| SCHEMBL16616261 | 0.91 | CAPN1 (0.49) | RELAABCG2CTSLCTSBABCB1 | |
| SCHEMBL16616259 | 0.91 | CAPN1 (0.49) | RELAABCG2CTSLCTSBABCB1 | |
| SCHEMBL16616371 | 0.91 | MAOB (0.49) | RELAABCG2ABCB1MAPTCYP3A4 | |
| SCHEMBL16616374 | 0.91 | MAOB (0.49) | RELAABCG2ABCB1MAPTCYP3A4 | |
| SCHEMBL16616463 | 0.91 | ABCG2 (0.47) | RELAABCG2ABCB1MAPTCYP1A1 | |
| SCHEMBL16616464 | 0.91 | ABCG2 (0.47) | RELAABCG2ABCB1MAPTCYP1A1 | |
| SCHEMBL16616567 | 0.91 | ABCG2 (0.53) | RELAABCG2CTSLCTSBABCB1 | |
| SCHEMBL16616565 | 0.91 | ABCG2 (0.53) | RELAABCG2CTSLCTSBABCB1 | |
| SCHEMBL16616113 | 0.91 | MAPT (0.50) | RELAABCG2CTSLCTSBABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006451-B1 | 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20150099888-A1 | 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099888-A1 | 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof | HCCS, WEE2, WEE1 | RELA 1949/4885ABCG2 289/4885CTSL 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.